Main Navigation

Executive Committee

Carleigh Baudoin, MPH

 

Ms. Baudoin holds a Bachelor of Arts degree in anthropology from Louisiana State University and a Master of Public Health degree from Tulane University School of Public Health and Tropical Medicine. She has over six years of public health experience and currently serves as Manager of the Chronic Disease Branch at the Department of State Health Services.  In this role, she oversees the Texas Heart Attack and Stroke Data Collection Initiative.  In addition to this project, Ms. Baudoin manages six other chronic disease-related programs that emphasize community health and health systems improvement.

 

 

 

Robin L. Brey, M.D.

Robin L. Brey, M.D.


Dr. Brey
is Professor and Chair of the Department of Neurology, and Edna Smith Dielmann Distinguished University Chair at the University of Texas Health Science Center at San Antonio (UTHSCSA). She was instrumental in creating a Joint Commission certified Primary Stroke Center at University Hospital, San Antonio, TX. Her research interests include the study of the relationship between antiphospholipid antibodies and stroke as well as neuropsychiatric manifestations of Systemic Lupus Erythematosus (NPSLE). Dr. Brey has participated in 3 expert panels on antiphospholipid antibodies (aPL) to help establish the appropriate criteria for clinical and laboratory diagnosis of the aPL Syndrome for research purposes. Dr. Brey has been the Principal Investigator on grants from the NIH and the American Heart Association. Formerly a member of the American Academy of Neurology (AAN) Board of Directors, Dr. Brey currently serves as the Editor-in-Chief of Neurology Now, the AAN publication for neurology patients, their families and the lay public.

 

Salvador-Cruz-Flores

Salvador Cruz-Flores, M.D., M.P.H.


Dr. Cruz-Flores 
is Professor and Chair of Neurology at Texas Tech University Health Sciences Center-El Paso. He attended medical school at the Universidad Autonoma de Nuevo Leon in Monterrey, Mexico and trained in Internal Medicine and Neurology at the Universidad Autonoma de Nuevo Leon. Dr. Cruz-Flores completed a neurology residency and a two-year fellowship in cerebrovascular diseases and neurocritical care at Saint Louis University. He also obtained a Masters degree in Public Health (Epidemiology) from Saint Louis University School of Public Health. Dr. Cruz-Flores is board certified in Neurology, Vascular Neurology, Neuro-Imaging, and Neuro-Critical Care.

 

 

 

Mark Goldberg, M.D.

Mark Goldberg, M.D.


Dr. Goldberg
is Professor and Chair of the Department of Neurology and Neurotherapeutics at UT Southwestern Medical Center in Dallas. Previously, Dr. Goldberg was professor of neurology and founding director of the Hope Center for Neurological Disorders at Washington University in St. Louis. He earned his medical degree from Columbia University after graduating from Harvard University with a bachelor’s degree in biology. He completed his neurology residency at Stanford University, where he also was a postdoctoral research fellow. Dr. Goldberg is board certified in neurology and vascular neurology. His research interests are in white matter injury and mechanisms of recovery after stroke. Under his leadership, UT Southwestern is undergoing rapid growth in clinical and translational neuroscience, with state-of the-art facilities for drug and device testing, and new initiatives to support collaborative research on brain disease therapy.

 

 

James Grotta, M.D.

James Grotta, M.D.


Dr. Grotta
is former Professor and Chairman of the Department of Neurology at the University of Texas Medical School at Houston.  Dr. Grotta first joined the University of Texas – Houston Medical School faculty in 1979. His research focuses on development of new therapies for acute stroke patients. He has been funded by the NIH for translational research from laboratory to bedside, and has been a leader of many clinical research studies of both thrombolytic drugs and cytoprotective agents after stroke. Dr. Grotta has built a collaborative network between the UT Stroke Team, Memorial Hermann Hospital, Houston Fire Department-Emergency Medical Services, and other regional stroke centers to increase the delivery of appropriate therapy to acute stroke patients in Houston, one of the first such networks in the country. In 2014, he moved his practice to Memorial Hermann Hospital to put into operation and evaluate the first Mobile Stroke Unit in the U.S. — an ambulance equipped with a CT scanner and staffed by Dr Grotta or another Vascular Neurologist, nurse, paramedic and CT tech to take emergency department evaluation and treatment directly to the acute stroke patient.  Dr. Grotta received the Feinberg Award for Excellence in Clinical Stroke from the American Heart Association (AHA) in 1999, the AHA Physician of the Year Award for 2006, the Eugene Braunwald Award for Mentoring in 2010, and awards for teaching excellence at UT Medical School for 14 years. He has authored or co-authored more than 300 articles in peer-reviewed journals.

 

Thomas A. Kent, M.D.

Thomas A. Kent, M.D.


Dr. Kent
is Professor, Director of Cerebrovascular Research and Education, and Co-Director of the Stroke OUtcomes Laboratory (SOUL) in the Department of Neurology at the Baylor College of Medicine in Houston, Texas. He is also Chief of Neurology and Director of the MEDVAMC Stroke Program at the Michael E. DeBakey VA Medical Center. The cerebrovascular research program at the Baylor College of Medicine encompasses 3 major hospitals, each a certified stroke center caring for a large and diverse population. Dr. Kent is a Fellow of the American Heart Association and has been a member and or/Chair of several AHA and NIH grant review committees. He is recognized as a US News Top Doctor in America. His own research spans from the basic science of oxidative stress in the nervous system, clinical trials of novel intravenous drug combinations for acute ischemic stroke, and development of outcome methodologies as Co-Director of the Stroke Outcomes Laboratory. He has a special interest in diabetes and hyperglycemia, the mechanisms by which they influence stroke outcomes and their role in the poor outcomes seen especially in minority populations.

 

BethLynn Maxwell, Ph.D., J.D.


Dr. Maxwell
is Chief Health Research Officer in the Office of Health Affairs and Associate General Counsel – Legal Expert in the Office of General Counsel at The University of Texas System. Her main responsibility is to develop, manage, implement and evaluate several new UT System health initiatives (e.g., clinical trials collaborations, collaboration among the CTSA programs at 5 UT System health institution, biobank consortium, etc.). Additionally, Dr. Maxwell supports the UT System health institutions in developing, implementing, and overseeing research policies and procedures. Dr. Maxwell joined the Office of General Counsel in 1997 as a patent attorney. Before joining UT, Dr. Maxwell was a patent attorney with Fish & Richardson P.C. in Houston, TX. Previously, she oversaw and managed a tissue culture core research laboratory and performed research in the Department of Cell Biology, Baylor College of Medicine, Houston, TX.  She received a Ph.D. and M.S. in Molecular Biology from The University of Texas Health Science Center at Houston, Graduate School of Biomedical Sciences and a J.D. from South Texas College of Law.


J. Neal Rutledge, M.D., FACR

J. Neal Rutledge, M.D., FACR

 

Dr. Rutledge is Chairman of the Texas Council Cardiovascular Disease and Stroke (DSHS) and Medical Director of the Imaging Research Center at UT Austin. He attended medical school at University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 1976-1980; and Imperial College School of Medicine, London, England 1979. His residency in diagnostic radiology was completed at Baptist Medical Center, Oklahoma City. He also did a fellowship in diagnostic neuroradiology and neurointerventional surgery at Columbia University, Columbia Presbyterian Hospital, Neurological Institute, New York City, New York, 1984-1986.

 

 

Sean-Savitz-lss

Sean I. Savitz, M.D.


Dr.
Savitz is a tenured Professor of Neurology, holds the Frank M. Yatsu Chair in Neurology, and directs the Stroke Program at the University of Texas Medical School in Houston.  He graduated from Harvard College, received his MD from Albert Einstein College of Medicine, and completed neurology residency training and a cerebrovascular fellowship at the Harvard Medical School Neurology Training Program.  He and his team run one of the largest academic stroke programs in the world, testing novel treatments for patients with ischemic stroke and brain hemorrhage.  Dr. Savitz oversees a bidirectional, translational laboratory and clinical research program on cell therapies in stroke and is conducting some of the first clinical trials testing cell therapies in stroke patients.  He also oversees a fellowship program to train stroke specialists and has won several teaching awards both in Boston and at UTHealth.  He has been funded by grants from the National Institute of Health, the Howard Hughes Medical Institute, and the American Heart Association, and is an author of over 100 publications in the biomedical literature.

 

steven-warach-lss

Steven Warach, M.D., Ph.D.


Dr. Warach
graduated from Michigan State University with a doctorate in neuroscience and psychology. He received his medical degree and neurology residency training at Harvard Medical School, before joining the Harvard Medical School faculty in 1993, as Chief of the Division of Cerebrovascular Diseases at Beth Israel Hospital. In 1999, he was recruited by the National Institutes of Neurological Disorders and Stroke as Senior Investigator and Chief of the Section of Stroke Diagnostics and Therapeutics, a translational clinical research program in acute stroke that established the first stroke centers in Washington DC and Suburban Maryland. In 2011, he was recruited by University of Texas Southwestern Medical Center and the Seton Healthcare Family to serve as Professor and founding Executive Director of the Seton/UT Southwestern Clinical Research Institute of Austin. Dr. Warach’s research is internationally recognized as introducing advanced MRI methods for more accurate diagnosis of stroke into clinical practice and for pioneering patient-specific, imaging-defined therapeutic targets in the development of new stroke therapies.

Facebook
Twitter
EMAIL